Table 5_Therapeutic potential of luteolin in central precocious puberty: insights from a danazol-induced rat model.docx by Zhijian Zha (19451405)

“…</p>Results<p>In the danazol-induced CPP model, luteolin treatment significantly decreased the abundances of Estradiol (E2), luteinizing hormone serum, and follicle-stimulating hormone in sera; reduced organ coefficients and ovarian and uterine wet weights; and delayed vaginal opening. …”

Table 2_Detection of fusion events by RNA sequencing in FFPE versus freshly frozen colorectal cancer tissue samples.xlsx by Maxim Sorokin (4379848)

“…We detected no statistically significant difference in the number of chimeric transcripts in FFPE and FF RNAseq profiles. …”

Image 2_Hippocampus-sparing volume-modulated arc therapy in patients with World Health Organization grade II glioma: a feasibility study.jpeg by Renxian Xie (17044863)

“…Regarding the protection of OARs, HS VMAT plans were equally capable and even lowered the radiation dosages to the brainstem (35.56 vs. 41.74 Gy, p = 0.017) and spinal cord (1.34 vs. 1.43 Gy, p = 0.006). Notably, HS VMAT plans markedly decreased doses to the ipsilateral hippocampus and the contralateral hippocampus, demonstrating its efficacy in hippocampal dose reduction.…”

<b>Patterns</b><b> and drivers of </b><b>plant C:N:P stoichiometry</b><b> across a 3000 km aridity gradient</b> by Jianzhao Wu (19185964)

“…Below this threshold (AI < 0.7), the leaf C:P and N:P ratios decreased as AI increased, and N limitation became more evident. …”

Table 2_Evolving landscape of female cancers along with attributable risk factors in China from 1990 to 2021, and projections to 2040.xlsx by Yali Han (4676677)

“…Cervical cancer saw a slight increase in ASIR (EAPC: 0.88), a substantial increase in ASPR (EAPC: 2.50), but decreases in ASMR and ASDR (EAPC: −1.05 and −1.07). …”

Table 9_Exploring Histoplasma species seroprevalence and risk factors for seropositivity in The Gambia’s working equid population: Baseline analysis of the Tackling Histoplasmosis... by Tessa Rose Cornell (15460726)

“…In horses, two multivariable models explained the maximum amount of data variability. Model 1 demonstrated increased odds of seropositivity in mares [odds ratio (OR) = 2.90 95% CI 1.70–4.95, p < 0.001] and decreased odds in horses <2.5 years (OR = 0.46 95% CI 0.22–0.95, p = 0.04; reference: ≥4.5 years). …”

Table 2_Exploring Histoplasma species seroprevalence and risk factors for seropositivity in The Gambia’s working equid population: Baseline analysis of the Tackling Histoplasmosis... by Tessa Rose Cornell (15460726)

“…In horses, two multivariable models explained the maximum amount of data variability. Model 1 demonstrated increased odds of seropositivity in mares [odds ratio (OR) = 2.90 95% CI 1.70–4.95, p < 0.001] and decreased odds in horses <2.5 years (OR = 0.46 95% CI 0.22–0.95, p = 0.04; reference: ≥4.5 years). …”

Table 10_Exploring Histoplasma species seroprevalence and risk factors for seropositivity in The Gambia’s working equid population: Baseline analysis of the Tackling Histoplasmosis... by Tessa Rose Cornell (15460726)

“…In horses, two multivariable models explained the maximum amount of data variability. Model 1 demonstrated increased odds of seropositivity in mares [odds ratio (OR) = 2.90 95% CI 1.70–4.95, p < 0.001] and decreased odds in horses <2.5 years (OR = 0.46 95% CI 0.22–0.95, p = 0.04; reference: ≥4.5 years). …”

Table 3_Exploring Histoplasma species seroprevalence and risk factors for seropositivity in The Gambia’s working equid population: Baseline analysis of the Tackling Histoplasmosis... by Tessa Rose Cornell (15460726)

“…In horses, two multivariable models explained the maximum amount of data variability. Model 1 demonstrated increased odds of seropositivity in mares [odds ratio (OR) = 2.90 95% CI 1.70–4.95, p < 0.001] and decreased odds in horses <2.5 years (OR = 0.46 95% CI 0.22–0.95, p = 0.04; reference: ≥4.5 years). …”

Table 8_Exploring Histoplasma species seroprevalence and risk factors for seropositivity in The Gambia’s working equid population: Baseline analysis of the Tackling Histoplasmosis... by Tessa Rose Cornell (15460726)

“…In horses, two multivariable models explained the maximum amount of data variability. Model 1 demonstrated increased odds of seropositivity in mares [odds ratio (OR) = 2.90 95% CI 1.70–4.95, p < 0.001] and decreased odds in horses <2.5 years (OR = 0.46 95% CI 0.22–0.95, p = 0.04; reference: ≥4.5 years). …”

Table 6_Exploring Histoplasma species seroprevalence and risk factors for seropositivity in The Gambia’s working equid population: Baseline analysis of the Tackling Histoplasmosis... by Tessa Rose Cornell (15460726)

“…In horses, two multivariable models explained the maximum amount of data variability. Model 1 demonstrated increased odds of seropositivity in mares [odds ratio (OR) = 2.90 95% CI 1.70–4.95, p < 0.001] and decreased odds in horses <2.5 years (OR = 0.46 95% CI 0.22–0.95, p = 0.04; reference: ≥4.5 years). …”

Table 5_Exploring Histoplasma species seroprevalence and risk factors for seropositivity in The Gambia’s working equid population: Baseline analysis of the Tackling Histoplasmosis... by Tessa Rose Cornell (15460726)

“…In horses, two multivariable models explained the maximum amount of data variability. Model 1 demonstrated increased odds of seropositivity in mares [odds ratio (OR) = 2.90 95% CI 1.70–4.95, p < 0.001] and decreased odds in horses <2.5 years (OR = 0.46 95% CI 0.22–0.95, p = 0.04; reference: ≥4.5 years). …”

Table 4_Exploring Histoplasma species seroprevalence and risk factors for seropositivity in The Gambia’s working equid population: Baseline analysis of the Tackling Histoplasmosis... by Tessa Rose Cornell (15460726)

“…In horses, two multivariable models explained the maximum amount of data variability. Model 1 demonstrated increased odds of seropositivity in mares [odds ratio (OR) = 2.90 95% CI 1.70–4.95, p < 0.001] and decreased odds in horses <2.5 years (OR = 0.46 95% CI 0.22–0.95, p = 0.04; reference: ≥4.5 years). …”

Table 7_Exploring Histoplasma species seroprevalence and risk factors for seropositivity in The Gambia’s working equid population: Baseline analysis of the Tackling Histoplasmosis... by Tessa Rose Cornell (15460726)

“…In horses, two multivariable models explained the maximum amount of data variability. Model 1 demonstrated increased odds of seropositivity in mares [odds ratio (OR) = 2.90 95% CI 1.70–4.95, p < 0.001] and decreased odds in horses <2.5 years (OR = 0.46 95% CI 0.22–0.95, p = 0.04; reference: ≥4.5 years). …”

Data Sheet 2_Duodenal obstruction due to two congenital bands: a case report and literature review.pdf by Shiqiu Xiong (238109)

“…Physical examination revealed abdominal tenderness and decreased bowel sounds. Contrast x-ray showed an obstructed passage of contrast through the third part of the duodenum. …”

Data Sheet 3_Duodenal obstruction due to two congenital bands: a case report and literature review.pdf by Shiqiu Xiong (238109)

“…Physical examination revealed abdominal tenderness and decreased bowel sounds. Contrast x-ray showed an obstructed passage of contrast through the third part of the duodenum. …”

Data Sheet 3_Global trends in esophageal cancer: sex and age disparities in health inequalities from 1990 to 2021, with projections to 2050.pdf by Ying Liu (18461)

“…Background<p>Esophageal cancer remains one of the deadliest cancers globally, highlighting significant health challenges and socioeconomic disparities. …”

Data Sheet 4_Global trends in esophageal cancer: sex and age disparities in health inequalities from 1990 to 2021, with projections to 2050.pdf by Ying Liu (18461)

“…Background<p>Esophageal cancer remains one of the deadliest cancers globally, highlighting significant health challenges and socioeconomic disparities. …”

Data Sheet 5_Global trends in esophageal cancer: sex and age disparities in health inequalities from 1990 to 2021, with projections to 2050.pdf by Ying Liu (18461)

“…Background<p>Esophageal cancer remains one of the deadliest cancers globally, highlighting significant health challenges and socioeconomic disparities. …”

Data Sheet 6_Global trends in esophageal cancer: sex and age disparities in health inequalities from 1990 to 2021, with projections to 2050.pdf by Ying Liu (18461)

“…Background<p>Esophageal cancer remains one of the deadliest cancers globally, highlighting significant health challenges and socioeconomic disparities. …”